Market revenue in 2020 | USD 2,377.5 million |
Market revenue in 2028 | USD 6,676.1 million |
Growth rate | 13.8% (CAGR from 2020 to 2028) |
Largest segment | Oral |
Fastest growing segment | Injectable |
Historical data covered | 2017 - 2019 |
Base year for estimation | 2020 |
Forecast period covered | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Topical, Injectable, Oral |
Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.
Oral was the largest segment with a revenue share of 39% in 2020. Horizon Databook has segmented the Europe atopic dermatitis drugs market based on topical, injectable, oral covering the revenue growth of each sub-segment from 2017 to 2028.
Increasing prevalence of atopic dermatitis, coupled with growing investments in atopic dermatitis research initiatives, is expected to drive Europe’s market. However, the current European economic crisis and presence of uneven reimbursement policies act as market restraints.
The prevalence of atopic dermatitis is much higher in Northern Europe than Eastern Europe. For instance, the prevalence of atopic dermatitis in adolescents in Denmark, Finland, Bulgaria, and Hungary is over 15%. Owing to the prevalence being higher than the global average of 7.3%, the demand for treatment is higher in Europe.
As per the British Journal of Dermatology in 2020, the first treatment preference of dermatologists in this region was phototherapy, with an 84.7% prescription rate. This was followed by use of systemic therapies, such as oral corticosteroids.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe atopic dermatitis drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Europe atopic dermatitis drugs market from 2017 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account